Ionis Pharmaceuticals Inc (NASDAQ:IONS) SVP C Frank Bennett sold 2,696 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $51.76, for a total transaction of $139,544.96. Following the completion of the sale, the senior vice president now directly owns 21,810 shares in the company, valued at approximately $1,128,885.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) opened at $51.12 on Thursday. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals Inc has a fifty-two week low of $37.26 and a fifty-two week high of $65.51. The firm has a market cap of $6,360.00, a PE ratio of 365.14 and a beta of 2.86.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its holdings in shares of Ionis Pharmaceuticals by 5.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 401,980 shares of the company’s stock worth $20,220,000 after purchasing an additional 20,246 shares during the last quarter. Sicart Associates LLC grew its holdings in shares of Ionis Pharmaceuticals by 2.3% in the 4th quarter. Sicart Associates LLC now owns 398,072 shares of the company’s stock worth $20,023,000 after purchasing an additional 9,050 shares during the last quarter. AXA bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth about $5,202,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth about $100,000. Finally, GSA Capital Partners LLP grew its holdings in shares of Ionis Pharmaceuticals by 10.9% in the 3rd quarter. GSA Capital Partners LLP now owns 23,893 shares of the company’s stock worth $1,211,000 after purchasing an additional 2,348 shares during the last quarter. 91.40% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have issued reports on IONS. BidaskClub lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. BMO Capital Markets boosted their price target on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th. Morgan Stanley boosted their price target on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $50.76.

TRADEMARK VIOLATION WARNING: “Ionis Pharmaceuticals Inc (IONS) SVP Sells $139,544.96 in Stock” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2018/01/18/ionis-pharmaceuticals-inc-ions-svp-sells-139544-96-in-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.